Dr Miroslav Mikolášik (Slovakia)
MEPs speak out on dementia
AE:From a policy makers´ perspective, why do you think it is important to bring the challenge of Alzheimer’s disease to the front and centre of European Parliament and what could be done to meet this public health challenge?
MM:Alzheimer’s disease is not an isolated problem of a few countries. It is a common challenge for the whole European and global society, which requires international cooperation. It seems to be one of the biggest challenges of the 21st century with its impact not only on human health but also on the economies of states and society as a whole.
In 2011, the European Parliament encouraged the EU member states to set up national action plans on Alzheimer’s and other forms of dementia.
Their objectives are wide-ranging: to reduce the risk of dementia but also to create a more inclusive society for affected people who will be more visible in aging European societies.
In March 2016, the second Joint action on Alzheimer’s, known as ALCOVE, was launched focusing on post-diagnostic support, use of medical products and care for family carers.
The goal we want to reach one day is to be able to treat underlying disease and stop or delay cell damage, which leads to the worsening of symptoms. This vision requires financial support for research from the state but also enough volunteers to complete clinical trials, whose absence is often identified as one of the mains obstacles.
Last Updated: Thursday 20 April 2017